Literature DB >> 28887358

First-Ever CAR T-cell Therapy Approved in U.S.

.   

Abstract

The first chimeric antigen receptor T-cell therapy, tisagenlecleucel, received FDA approval for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia who haven't responded to standard therapy or who have relapsed at least twice. ©2017 American Association for Cancer Research.

Entities:  

Year:  2017        PMID： 28887358     DOI： 10.1158/2159-8290.CD-NB2017-126

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  17 in total

1.  Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra.

Authors:  Shashidhar S Jatiani; Adolfo Aleman; Deepu Madduri; Ajai Chari; Hearn Jay Cho; Shambavi Richard; Joshua Richter; Joshua Brody; Sundar Jagannath; Samir Parekh
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-05-11

Review 2.  The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy.

Authors:  Jessica B Foster; David M Barrett; Katalin Karikó
Journal:  Mol Ther       Date:  2019-02-02       Impact factor: 11.454

Review 3.  Trial watch: DNA-based vaccines for oncological indications.

Authors:  Stefano Pierini; Renzo Perales-Linares; Mireia Uribe-Herranz; Jonathan G Pol; Laurence Zitvogel; Guido Kroemer; Andrea Facciabene; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

Review 4.  The Landscape of Early Clinical Gene Therapies outside of Oncology.

Authors:  Laure Rittié; Takis Athanasopoulos; Miguel Calero-Garcia; Marie L Davies; David J Dow; Steven J Howe; Alastair Morrison; Ida Ricciardelli; Aurore Saudemont; Laurent Jespers; Timothy M Clay
Journal:  Mol Ther       Date:  2019-09-06       Impact factor: 11.454

Review 5.  [CARs, CRS and neurotoxicity: severe complications after administration of immunotherapy : Essentials for intensivists].

Authors:  J Prinz; Y d'Hargues; P Gödel; A Shimabukuro-Vornhagen; M Kochanek; B Böll
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-12-13       Impact factor: 0.840

Review 6.  Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.

Authors:  May Daher; Katayoun Rezvani
Journal:  Curr Opin Immunol       Date:  2018-03-30       Impact factor: 7.486

Review 7.  Immunotherapy for pediatric brain tumors: past and present.

Authors:  Jessica B Foster; Peter J Madsen; Meenakshi Hegde; Nabil Ahmed; Kristina A Cole; John M Maris; Adam C Resnick; Phillip B Storm; Angela J Waanders
Journal:  Neuro Oncol       Date:  2019-10-09       Impact factor: 12.300

Review 8.  Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.

Authors:  Zhenguang Wang; Weidong Han
Journal:  Biomark Res       Date:  2018-01-22

Review 9.  Cytokine release syndrome.

Authors:  Alexander Shimabukuro-Vornhagen; Philipp Gödel; Marion Subklewe; Hans Joachim Stemmler; Hans Anton Schlößer; Max Schlaak; Matthias Kochanek; Boris Böll; Michael S von Bergwelt-Baildon
Journal:  J Immunother Cancer       Date:  2018-06-15       Impact factor: 13.751

Review 10.  Chimeric non-antigen receptors in T cell-based cancer therapy.

Authors:  Jitao Guo; Andrew Kent; Eduardo Davila
Journal:  J Immunother Cancer       Date:  2021-08       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.